))
Controlling Costs through Continuous Manufacturing of Biopharmaceuticals — A Conversation with Jon Gunther of Just – Evotec Biologics
Manage episode 424223851 series 3580470
Content provided by Executive Platforms. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Executive Platforms or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
At the 2023 edition of the Biomanufacturing World Summit series we sat down with Jon Gunther of Just – Evotec Biologics to talk about why biopharmaceutical manufacturing is behind the curve when it comes to controlling its costs, and what lessons senior leaders can take from other industries as they work to rein in expenses. One important idea explored at length is the advantage pivoting from batch manufacturing to continuous manufacturing would offer the Life Sciences in terms of reducing operating costs, costs of goods, labor costs, and more. What does making that switch look like in real terms? What do companies need to do to prepare their people, processes, and systems for change, and who can they look to for guidance and assistance as they transform themselves? How can companies model their product workflow and output before committing themselves to the transition, and what kind of platform will allow for the smoothest possible move between production models? Give this episode a listen for answers to these questions and more!
--
Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com
220 episodes
Share
